KINDEVA
SpecialtyKINDEVA is a specialty pharmaceutical company focused on Respiratory.
KINDEVA's Key Drugs
KINDEVA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
KINDEVA's Recent FDA Approvals
New NDA/BLA approvals for KINDEVA over the last two years — novel drugs only, excluding generics and label supplements.
KINDEVA's Therapeutic Areas
KINDEVA's approved drugs and pipeline span 1 therapeutic area, led by Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
KINDEVA's Top Competitors
KINDEVA's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
KINDEVA Pipeline Snapshot
KINDEVA has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1996-08-15
- Latest
- 2026-06-18
- Applications
- 2